An Ultra-Long-Acting Antibody Known as HBM9378/WIN378 Targeting TSLP Accomplishes Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

On September 8, 2026, HBM9378/WIN378, a very long-lasting antibody targeting thymic stromal lymphopoietin, has shown positive Phase Two results in asthma patients and is moving into Phase Three development. By targeting TSLP, the antibody tries to block an early cause of type two inflammation, possibly helping patients whose asthma is hard to control. This announcement is an important step for a treatment aimed at the inflammatory pathways involved in asthma.

Its long-lasting effect could allow for less frequent dosing, which is a useful feature for managing long-term lung diseases. The respiratory problems are increasing, and clinical experts moving into a Phase Three study show that the developers believe the treatment has enough promise to test in a larger group. If future trials confirm it works well and is safe, HBM9378/WIN378 could offer more treatment selections for people with poorly controlled asthma and increase interest in long-lasting biologic treatments.

Impact on the Biopharmaceutical Industry

The global biopharmaceuticals market size is calculated at USD 537.54 billion in 2025 and is predicted to increase from USD 616.02 billion in 2026 to approximately USD 1,983.73 billion by 2035, expanding at a CAGR of 13.95% from 2026 to 2035.

According to Precedence Research, the positive Phase Two results increase interest in new biologic treatments designed to deliver lasting control of chronic inflammatory diseases. HBM9378/WIN378 combines targeted TSLP blocking with a very long-lasting effect, which could set it apart in the competitive asthma biologics market. Strong Phase Three results could make long-lasting antibody treatments more appealing for lung disease development.

Success in Phase Three might encourage drug companies to develop treatments that allow for longer time between doses and control the disease well. The program could lead to substantial investment in antibodies that target early inflammation pathways. How well it competes will depend on how effective, safe, long-lasting, easy to use, and easy to produce it is.

Impact on the Respiratory Disease Vaccine Industry

The global respiratory disease vaccine market size was estimated at USD 101.10 billion in 2025 and is anticipated to reach around USD 123.77 billion by 2035, growing at a CAGR of 2.04% between 2026 and 2035.

According to Precedence Research, for respiratory healthcare, HBM9378/WIN378 could provide a more convenient treatment plan if its long-lasting effect is confirmed in later trials. The research focuses on manufacturing a vaccine through the TSLP antibody that could cure hard-to-control asthma with biologic treatment. Managing asthma often requires patients to stick to long-term treatments, so how often they need to take medicine is important for patients and doctors.

Clinical guidelines and doctors’ acceptance will decide its place in respiratory disease treatment. This option might be especially useful for patients who need advanced biological treatment. Additionally, healthcare providers will need clear proof that taking the medicine less controls the disease.

Impact on Asthma Treatment Industry

The global asthma treatment market size is valued at USD 28.96 billion in 2025 and is predicted to increase from USD 29.56 billion in 2026 to approximately USD 36.8 billion by 2035, expanding at a CAGR of 2.42% over the forecast period from 2026 to 2035.

According to Precedence Research, the asthma cure rate is low, and HBM9378/WIN378 is considered based on both its possible health benefits and cost-effectiveness. A very long-lasting therapy could lower how often patients need medicine and make treatment easier, but its overall value will depend on health results, price, and healthcare use.

Biologic treatments for asthma can be expensive over time, so how well the treatment works and how often it needs to be given are important factors. Healthcare providers will likely check if the treatment can minimize asthma attacks, hospital visits, and other costs linked to poorly controlled asthma. Additionally, showing clear improvements over current biologics will be crucial to getting good reimbursement and widespread market access.

Expert Opinion

From an expert perspective, moving HBM9378/WIN378 into Phase Three is an important step because it combines two useful features. Targeting an early inflammation pathway could give good disease control for the right asthma patients and a very long-lasting treatment effect. A longer time between doses may solve some practical problems with long-term biologic treatment. Success in Phase Two should be seen as a positive step, not proof of being better than others.

It will be important to see how this treatment compares with existing TSLP and other biologic therapies. The Phase Three study will need to show lasting effectiveness, good safety, and steady benefits for a larger group of patients. If its health benefits and easier dosing are confirmed, HBM9378/WIN378 could become a strong competitor in the changing asthma biologics market.